Prelude Therapeutics Incorporated

Prelude Therapeutics is a precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Its pipeline features highly selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, and it is leveraging expertise in targeted protein degradation to discover and develop next generation degrader antibody conjugates (DACs) with novel payloads. The company was founded in 2016 with the vision of bringing together the energy and collaborative culture of a start-up environment with seasoned experience in developing cancer medicines.

Prelude Therapeutics was founded in 2016 with the vision of bringing together the energy and collaborative culture of a start-up environment with seasoned experience in developing cancer medicines. Kris Vaddi, Ph.D. founded Prelude Therapeutics and has served as the Chief Executive Officer and member of the Board of Directors since 2016. Prior to founding Prelude, from 2014 to 2016, Dr. Vaddi served as Chief Executive Officer of Orsenix, LLC, a clinical stage biotechnology company. Previously, he held several roles at Incyte Corporation, starting as a Founding Scientist and an Executive Director in 2002, and most recently as a Senior Advisor from 2015 to 2016.

A leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients.

1. 1Home - Prelude Therapeuticspreludetx.com
2. 2Overview - Prelude Therapeuticspreludetx.com
3. 3Leadership - Prelude Therapeuticspreludetx.com
4. 4Prelude Therapeutics Incorporated (United States)wikidata.org